Tornvall P, Walldius G
Department of Internal Medicine, Karolinska Hospital, Stockholm, Sweden.
J Intern Med. 1991 Nov;230(5):415-21. doi: 10.1111/j.1365-2796.1991.tb00466.x.
Serum and lipoprotein lipid levels, oral glucose tolerance and side-effects were compared in an open cross-over study of 31 non-diabetic patients with hypertriglyceridaemia (type II B and IV) before and after 6 weeks of treatment with nicotinic acid (3 g daily) and acipimox (0.75 g daily), a new nicotinic acid-like drug, respectively. Acipimox was about equally potent in reducing serum and VLDL lipid levels and in increasing HDL cholesterol levels. Acipimox had no significant negative effects on glucose metabolism measured by an oral glucose tolerance test compared with nicotinic acid, which decreased the late glucose tolerance as well as the area under the glucose curve (P less than 0.05 for the difference between the two treatments). The incidence and severity of flush or any other recorded side-effects was higher after nicotinic acid treatment than after acipimox. In addition, no effects on laboratory parameters such as liver enzymes and uric acid were seen after treatment with acipimox. The results of this study demonstrate that acipimox is a satisfactory alternative to nicotinic acid in patients with hypertriglyceridaemia.
在一项开放交叉研究中，对31例非糖尿病性高甘油三酯血症（II B型和IV型）患者在分别接受烟酸（每日3g）和阿西莫司（每日0.75g，一种新型烟酸类似药物）治疗6周前后的血清和脂蛋白脂质水平、口服葡萄糖耐量及副作用进行了比较。阿西莫司在降低血清和极低密度脂蛋白（VLDL）脂质水平以及提高高密度脂蛋白（HDL）胆固醇水平方面的效力大致相同。与烟酸相比，阿西莫司经口服葡萄糖耐量试验测定对糖代谢无显著负面影响，烟酸会降低后期葡萄糖耐量以及葡萄糖曲线下面积（两种治疗方法之间的差异P<0.05）。烟酸治疗后潮红或任何其他记录的副作用的发生率和严重程度高于阿西莫司。此外，阿西莫司治疗后未观察到对肝酶和尿酸等实验室参数有影响。本研究结果表明，对于高甘油三酯血症患者，阿西莫司是烟酸的一种令人满意的替代药物。
